MorphImmune uses a platform technology of small-molecule, rapidly penetrating, cost-effective drug-targeting of errant immune cells.  We deliver drugs that can reprogram pro-inflammatory and pro-tumor immune cells to an anti-inflammatory and anti-tumor milieu.  Using immune cell specific ligands coupled with pathway re-programmers, the technology tackles core chronic and acute disease pathways.  This approach differentiates MorphImmune from other immune-biopharmaceuticals that block downstream changes once the immune cells have been hijacked. MorphImmune addresses immune changes at its core alterations.